111, Inc. filings document foreign-issuer current reports furnished on Form 6-K, primarily covering unaudited quarterly and annual financial results for its China healthcare platform. The disclosures report net revenues, gross segment profit, operating expenses, operating cash flow and segment activity tied to the company’s B2B and B2C healthcare businesses.
The filing record also describes the company’s transition toward an asset-light warehouse partnership model, including subsidiary divestitures that shifted certain fulfillment facilities into partner roles. These reports provide formal disclosure of business performance, margin trends, liquidity measures, ADR reporting status and material operating updates furnished to U.S. markets.
111, Inc. director Sun Jian David reported a mix of RSU grants and share sales. On May 11, 2026, he received 378,737 RSUs that vested in full on the grant date. On May 12, 2026, he received a further 413,168 RSUs that vest 25% on each of the first four anniversaries of May 12, 2026, with pro rata vesting if his service ends other than for cause.
Between May 26, 2026 and June 10, 2026, he sold 227,160 Class A ordinary shares tied to RSUs at prices between $0.22 and $0.27 per share. Footnotes state that 29,280 shares and 70,440 shares were sold to satisfy tax withholding obligations on RSU vesting. After these transactions, he directly holds 583,111 RSUs (Class A).
YI submitted a Form 144 notice relating to the proposed sale of 14,867 ADS, where each ADS represents 20 Class A ordinary shares. The filing lists a transaction date of 06/09/2026 and shows an insider, Sun Jian David, with sales of 4,986 ADS on that date and a listed value of $25,901.99.
The filing identifies Citigroup Global Markets as the broker and records the ADS class and related acquisition under a company share incentive plan dated 09/13/2019.
111, Inc. reported weak first quarter 2026 results as it continues shifting to an asset-light, platform-focused model. Net revenue was RMB2.36 billion (US$342.4 million), down 33.1% from the same period last year, mainly due to strategic optimization of its business mix.
Gross segment profit was RMB126.0 million (US$18.3 million), a decline of 35.4%. The company recorded a loss from operations of RMB20.0 million (US$2.9 million), versus a small profit a year ago, and a net loss of RMB26.8 million (US$3.9 million), which also widened on a non-GAAP basis.
Management highlighted growth in marketplace service revenue of 24.7% year over year, modest B2C revenue growth and a 34.6% reduction in fulfillment expenses, reflecting efficiency gains. However, cash, restricted cash and short-term investments fell to RMB396.6 million (US$57.5 million) from RMB611.3 million, and operating cash flow turned negative.
The company also detailed about RMB0.95 billion owed to investors in 1 Pharmacy Technology. It has repaid approximately RMB282.2 million, and investors holding 60.3% of the principal have agreed to restructure and extend redemption terms.
111, Inc. director Luo Jun Justin reported a mix of RSU awards and related share sales. He received grants of 378,737 and 413,168 RSUs, each representing one Class A ordinary share, with the larger grant vesting in stages from May 12, 2026. To satisfy tax withholding obligations tied to RSU vesting, 29,280 Class A shares were sold at $0.27 per share and 70,440 Class A shares were sold at $0.25 per share. After these compensation-related transactions, he holds 710,551 Class A shares directly.
111, Inc. director Sun Jian David reported a series of RSU-related transactions in Class A ordinary shares. He received grants of 378,737 RSUs on May 11, 2026 that vested in full on the grant date and 413,168 RSUs on May 12, 2026 that vest in four annual installments. On May 26, 2026 and May 27, 2026, a total of 99,720 Class A shares were sold solely to satisfy tax withholding obligations tied to RSU vesting, at prices of $0.27 and $0.25 per share. After these transactions, Sun directly holds 710,551 Class A shares.
111, Inc. director Chen Yang Luke reported RSU awards and related tax-share sales. He received grants of 54,759 and 413,168 RSUs (Class A), each representing one Class A ordinary share. As RSUs vested, he sold 1,440 and 3,400 Class A shares to satisfy tax withholding obligations, and held 589,382 Class A shares directly after the latest transaction.
Teo Nee Chuan reported acquisition or exercise transactions in this Form 4 filing.
111, Inc. director Teo Nee Chuan reported equity compensation in the form of restricted stock units (RSUs) tied to Class A ordinary shares. The filing shows grants of 378,737 RSUs that vest in full on May 11, 2026 and 413,168 RSUs granted on May 12, 2026, scheduled to vest in four equal annual installments from that date. Following the latest grant, Teo directly holds 811,889 RSUs representing the right to receive an equal number of Class A shares.
Chen Yang Luke reported acquisition or exercise transactions in this Form 4 filing.
111, Inc. director Chen Yang Luke reported multiple grants of restricted stock units (RSUs) tied to the company’s Class A ordinary shares. On May 12, 2026, he received 413,168 RSUs (Class A), each representing one Class A ordinary share. This award vests in four equal annual installments on the first through fourth anniversaries of May 12, 2026, with pro rata vesting in a year if his service ends other than for cause.
The filing also shows a separate grant of 54,759 RSUs (Class A) dated May 11, 2026, which fully vested on the grant date, and an earlier grant of 126,295 RSUs dated September 8, 2023. Following the most recent grant, Luke directly holds 594,222 Class A RSUs or shares, reflecting his equity-based compensation rather than open-market purchases or sales.
Luo Jun Justin reported acquisition or exercise transactions in this Form 4 filing.
111, Inc. director Luo Jun Justin reported awards of restricted stock units (RSUs) tied to the company’s Class A ordinary shares. On May 11, 2026, he received 378,737 RSUs that vest in full on the grant date. On May 12, 2026, he received a further 413,168 RSUs that vest 25% on each of the first four anniversaries of May 12, 2026, with pro rata vesting in a year if his service ends other than for cause. Earlier, on September 12, 2018, he was granted 18,366 RSUs. Following the most recent grant, his direct holdings reported in this filing include 810,271 RSUs.
Sun Jian David reported acquisition or exercise transactions in this Form 4 filing.
111, Inc. director Sun Jian David reported awards of restricted stock units (RSUs) tied to the company’s Class A ordinary shares. On May 11, 2026, he received 378,737 RSUs that vest in full on the grant date, giving an immediate right to the same number of Class A shares.
On May 12, 2026, he was granted a further 413,168 RSUs, scheduled to vest in four equal 25% installments on each anniversary of May 12, 2026, with pro rata vesting in certain termination scenarios. Earlier, on September 12, 2018, he had received 18,366 RSUs. Following the latest grant, his directly held RSUs total 810,271, reflecting compensation awards rather than open‑market share purchases or sales.